EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, IPSC: Century Therapeutics Inc

06 Nov 25 04:14
LAST:

0.5510

CHANGE:
 0.01		OPEN:
0.5598		HIGH:
0.5598		ASK:
0.0000		VOLUME:
1.4K
CHG(%):
1.57		PREV:
0.5598		LOW:
0.5510		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 250.55980.55980.55100.55101.4K
05 Nov 250.58010.58430.54500.55981.34M
04 Nov 250.58000.65000.56500.57302.59M
03 Nov 250.59770.61390.58300.60007.96M
31 Oct 250.59000.60000.57560.5831653.0K
30 Oct 250.57000.60860.55200.5920452.4K
29 Oct 250.62990.62990.57230.5767942.7K
28 Oct 250.59550.63000.59550.61981.17M
27 Oct 250.58610.60380.57130.6001806.8K
24 Oct 250.59500.60000.57130.5773888.1K

COMPANY PROFILE

Name:Century Therapeutics Inc
About:Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Sector:Healthcare
Industry:Biotechnology
Address:25 North 38th Street, Philadelphia, PA, United States, 19104
Website:https://www.centurytx.com
CUSIP:15673T100
CIK:0001850119
ISIN:US15673T1007
FIGI:BBG00PM8N5W0

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.37 
Forward P/E:-0.43 
PEG Ratio:-0.43 
Price to Sales:0.44 
Price to Book:0.24 
Profit Margin:-0.20 
Operating Margin:-0.25 
Return on Assets:-0.05 
Return on Equity:-0.11 
EPS Ratio:-0.28 
Revenue:114.13M 
Shares:86.39M 
Market Cap:47.6M 

TECHNICAL INDICATORS

MA5:0.574.1%
MA10:0.585.9%
MA20:0.574.1%
MA50:0.533.4%
MA100:0.550.3%
MA200:0.574.1%
RSI14:51.73
WPR14:-100.00 
MTM14:-0.02
ROC14:-0.03 
ATR:0.04 
Week High:0.6518.0%
Week Low:0.551.1%
Month High:0.6518.0%
Month Low:0.514.1%
Year High:1.83232.1%
Year Low:0.3461.2%